Literature DB >> 32760815

Inconsistencies in assessment of pain endpoints in radiotherapy for painful tumors: Analysis of original articles in the Green and Red Journals.

Tetsuo Saito1,2, Naoto Shikama3, Atsunori Yorozu4, Hikaru Kubota5, Kenta Murotani6, Kohsei Yamaguchi1, Natsuo Oya1, Naoki Nakamura7.   

Abstract

BACKGROUND AND
PURPOSE: Consistent assessment of the pain response is essential for adequately comparing treatment efficacy between studies. We studied the assessment of pain endpoints in radiotherapy for painful bone metastases (PBMs) and painful non-bone-metastasis tumors (PNTs).
MATERIAL AND METHODS: We performed a literature search in the Green (Radiotherapy and Oncology) and Red (International Journal of Radiation Oncology * Biology * Physics) Journals for full-length original articles published between 2009 and 2018. We only included articles that assessed palliation of tumor-related pain after radiotherapy. The data obtained included the definitions of pain response and assessment of non-index pain (pain other than that related to the irradiated tumors).
RESULTS: Among the 1812 articles identified using the journals' search function, 60 were included in the analysis. Thirty percent of the PBM articles and approximately half of the PNT articles did not report on analgesic use. Among the prospective studies, 68% of the articles on PBMs and 10% of the articles on PNTs used the International Consensus Endpoint. The PBM articles published in 2014-2018 utilized the International Consensus Endpoint more frequently than those published in 2009-2013 (p = 0.049). No articles reported information on non-index pain.
CONCLUSIONS: After the initial publication of the International Consensus Endpoint, the frequency of its use appears to have risen in PBM research; however, its use in PNT studies has been considerably limited. The International Consensus Endpoint should be consistently utilized in future studies on radiotherapy for painful tumors. Since none of the journal articles had investigated non-index pain, this issue may also needs to be addressed.
© 2020 The Author(s).

Entities:  

Keywords:  Analgesics; PBM, painful bone metastasis; PNT, painful non-bone-metastasis tumor; Pain endpoint; Pain response; Painful tumors; Palliative radiotherapy

Year:  2020        PMID: 32760815      PMCID: PMC7393456          DOI: 10.1016/j.ctro.2020.07.003

Source DB:  PubMed          Journal:  Clin Transl Radiat Oncol        ISSN: 2405-6308


Pain is common in cancer patients, contributing to poor physical and emotional well-being [1]. A systematic review on pain prevalence and pain severity in cancer patients showed that the prevalence rates of pain were 39.3% after curative treatment; 55.0% during anticancer treatment; and 66.4% in advanced, metastatic, or terminal disease [2]. Pain caused by tumors, including bone metastases [3], [4] and other tumors [5], [6], [7], [8], are major causes of cancer pain. Consistent assessment of the pain response is essential for adequately evaluating the treatment efficacy of radiotherapy for painful tumors. An international consensus was achieved on palliative radiotherapy endpoints for clinical trials in bone metastases to ensure consistent assessment of the pain response [9]; this was initially published in 2002 [9] and updated in 2012 [10]. According to the International Consensus Endpoint, a partial response is defined as a reduction in the index pain score by ≥ 2 without an increase in analgesic use, or a ≥ 25% reduction in analgesic use from baseline without an increase in the pain score [9], [10]. The International Consensus Endpoint, initially developed for research on painful bone metastases (PBMs), has also been shown to be associated with pain interference changes in treatment for painful non-bone-metastasis tumors (PNTs) [11]. To date, the frequency of the use of the International Consensus Endpoint is unknown in studies on both PBMs and PNTs The presence of non-index pain, the cause of which is not treated with radiotherapy, was recently demonstrated to be associated with poorer pain interference after palliative radiotherapy [12]. Even when the index pain is alleviated after radiotherapy, non-index pain may preclude the patients from deriving full benefits from palliative radiotherapy. Among studies on radiotherapy for painful tumors, the proportion reporting non-index pain endpoints is unknown. Since the initial publication of the International Consensus Endpoint, has the frequency of its use risen adequately? How often is non-index pain investigated? In the present study, we sought to determine the frequency of the use of the International Consensus Endpoint and non-index pain endpoints in studies on radiotherapy for PBMs and PNTs. We searched articles published in two of the largest and most influential radiation oncology journals, namely, the Radiotherapy and Oncology (Green Journal) and International Journal of Radiation Oncology * Biology * Physics (Red Journal).

Material and methods

Search strategy and article selection

We performed a literature search in the Green (Radiotherapy and Oncology) and Red (International Journal of Radiation Oncology * Biology * Physics) journals for full-length original articles published between 2009 and 2018; the last search was performed on November 17, 2019. As the International Consensus Endpoint was initially published in 2002 [9], we compared articles published in 2009–2013 and 2014–2018, considering the time frame between consensus agreement and its uptake by researchers. Articles that contained the term “pain” were identified using the online search function of each journal. For the present study, we only included articles that assessed palliation of tumor-related pain after radiotherapy. More specifically, we included articles in which the number or proportion of patients who experienced pain response (or other terms with similar meanings, such as pain alleviation, pain palliation, or improvement in pain) was described. We did not restrict the methods of assessing pain response to specific ones; i.e., we included studies in which pain response was assessed based on pain scales, one of the subscales of quality of life, and subjective patient evaluation. In addition to articles whose primary endpoint was pain response, those in which pain response was the secondary outcome measure were also included in the present analysis. The following articles were excluded: editorials or reviews, case reports (<10 patients), and studies using radiopharmaceuticals, particle radiotherapy, brachytherapy, radiotherapy for benign disease, intraoperative radiotherapy, and preoperative radiotherapy. The title/abstract screening and the subsequent assessment of full-text articles for eligibility were performed by one radiation oncologist (TS).

Data extraction

We grouped articles based on the painful tumor types, for which radiotherapy was administered as follows: PBMs and PNTs. Studies that included both PBMs and PNTs were included in the PNT group. Our primary goal was to investigate the definition of the pain response after radiotherapy for painful tumors. Additional information obtained included the study design (i.e., prospective or retrospective and randomized controlled trial or not), primary endpoints of the study, scales for measuring pain intensity, assessment of analgesic use, assessment of non-index pain (i.e., pain other than that caused by the irradiated tumors), assessment of quality of life or pain interference with daily activities, and assessment of symptoms other than pain. Articles that utilized prospectively collected databases were classified as prospective studies. Those involving secondary analyses of previously published randomized controlled trial data were not classified as randomized controlled trials in the present study.

Statistical analysis

The proportion of articles that used the International Consensus Endpoint were compared between the articles published in 2009–2013 and 2014–2018, using the Fisher’s exact test. The statistical tests were two-tailed, and p values < 0.05 were considered statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results

Among the 1812 articles identified through the journals’ online search function, 60 were included in the study (Fig. 1). The characteristics of the included studies are presented in Table 1 (PBMs) and Table 2 (PNTs). Approximately 70% of the PBM articles and 40% of the PNT articles had a prospective study design. As a scale for measuring pain intensity, the 11-point numeric rating scale was utilized in approximately half of the articles that investigated PBMs; in contrast, only 2 (9%) studies in the PNT group utilized the numeric rating scale. Over a half of the articles on PNTs did not report on scales measuring pain intensity. In approximately half of the articles on PBMs, the International Consensus Endpoint was employed to define the pain response; conversely, it was utilized in only 1 article (4%) on PNTs. Among the PNT articles, 70% assessed the pain response based only on pain intensity. The PBM articles published in 2014–2018 utilized the International Consensus Endpoint more frequently than those published in 2009–2013 (p = 0.049); however, this trend was not observed for PNT articles (p = 0.35) (Fig. 2). No PBM or PNT articles reported data on non-index pain, the cause of which was not irradiated.
Fig. 1

Flow diagram of study inclusion.

Table 1

Characteristics of articles that investigated painful bone metastases.

CharacteristicGreen JournalRed JournalTotal
No.%No.%No.%
Total number of articles that studied pain palliation owing to radiation therapy101002710037100
Study design
 Prospective1010015562568
 Retrospective0012441232
Randomized controlled trial
 No88026963492
 Yes2201438
Symptom palliation as primary endpoint
 No22010371232
 Yes88017632568
Scales for measuring pain intensity
 11-point numeric rating scale55014521951
 Visual analog scale220519719
 Others3*300038
 Not reported00830822
Assessment of analgesic usage
 No11010371130
 Yes99017632670
Definition of pain response
 International Consensus Endpoint published in 2002330519822
 International Consensus Endpoint published in 20125505191027
 Based on both, pain intensity and analgesic use110415514
 Based only on pain intensity11013481438
Assessment of pain other than index pain caused by the irradiated tumors
 No101002710037100
 Yes000000
Assessment of quality of life or symptom interference
 No33018672157
 Yes7709331643
Assessment of any symptoms other than pain
 No88019702773
 Yes2208301027

*Overall, 4-point scales were used in 2 studies, and a 5-point scale was used in 1 study.

Table 2

Characteristics of articles that investigated painful non-bone-metastasis tumors.

CharacteristicGreen Journal
Red Journal
Total
No.%No.%No.%
Total number of articles that studied pain palliation owing to radiation therapy51001810023100
Study design
 Prospective3607391043
 Retrospective24011611357
Randomized controlled trial
 No480181002296
 Yes1200014
Symptom palliation as primary endpoint
 No2408441043
 Yes36010561357
Scales for measuring pain intensity
 11-point numeric rating scale0021129
 Visual analog scale00317313
 Others1*204 †22522
 Not reported4809501357
Assessment of analgesic usage
 No4808441252
 Yes12010561148
Definition of pain response
 International Consensus Endpoint published in 2002000000
 International Consensus Endpoint published in 2012001614
 Based on both, pain intensity and analgesic use00633626
 Based only on pain intensity510011611670
Assessment of pain other than index pain caused by the irradiated tumors
 No51001810023100
 Yes000000
Assessment of quality of life or symptom interference
 No24013721565
 Yes360528835
Assessment of any symptoms other than pain
 No00739730
 Yes510011611670

*A 4-point scale was used in 1 study.

†A 4-point scale was used in 3 studies, and the Kersh-Hazra scale was used in 1 study.

Fig. 2

Definition of pain response according to the years of publication. Abbreviations: ICE = International Consensus Endpoint; PBM = painful bone metastases; PNT = painful non-bone-metastasis tumors.

Flow diagram of study inclusion. Characteristics of articles that investigated painful bone metastases. *Overall, 4-point scales were used in 2 studies, and a 5-point scale was used in 1 study. Characteristics of articles that investigated painful non-bone-metastasis tumors. *A 4-point scale was used in 1 study. †A 4-point scale was used in 3 studies, and the Kersh-Hazra scale was used in 1 study. Definition of pain response according to the years of publication. Abbreviations: ICE = International Consensus Endpoint; PBM = painful bone metastases; PNT = painful non-bone-metastasis tumors. Pain assessment in the included prospective articles is presented in Fig. 3. In 11 (31%) of the 36 articles published in 2009–2013, enrollment started earlier than 2002, when the International Consensus Endpoint was initially published. In 6 (25%) of the 24 articles published in 2014–2018, enrollment started earlier than 2002. While 64% articles on PBMs utilized the 11-point numeric rating scale, only 1 (10%) PNT article utilized this scale; 84% and 50% of the articles in the PBM and PNT groups, respectively, reported any information on analgesic use. Although the International Consensus Endpoint was most frequently used to define the pain response in articles on PBMs, 32% defined it differently. In the PNT group, the International Consensus Endpoint was utilized in only 1 (10%) article.
Fig. 3

Summary of prospective studies. Abbreviations: NRS = numeric rating scale; VAS = visual analog scale; NR = not reported; ICE = International Consensus Endpoint; PBM = painful bone metastases; PNT = painful non-bone- metastasis tumors.

Summary of prospective studies. Abbreviations: NRS = numeric rating scale; VAS = visual analog scale; NR = not reported; ICE = International Consensus Endpoint; PBM = painful bone metastases; PNT = painful non-bone- metastasis tumors.

Discussion

We found that the assessment of pain intensity, analgesic use, and pain response was not sufficiently consistent between the included studies. This inconsistency was demonstrated in some and many of the articles on PBMs and PNTs, respectively. After the initial publishing of the International Consensus Endpoint in 2002, the frequency of its use appears to have risen for more than ten years in PBMs. This increase in the frequency of use of the consensus endpoint is encouraging, in view of the difficulties in introducing evidence and clinical guidelines into routine practice [13], [14]. The proportion of studies that commenced accrual before 2002 shows one of the reasons why uptake of consensus by papers can be slow. Future studies might more frequently use the consensus endpoint, considering that 31% of the studies published in 2009–2013 and 25% of those published in 2014–2018 commenced enrollment before 2002, and thus, were not able to use the International Consensus Endpoint to assess pain response. In contrast, the International Consensus Endpoint was scarcely utilized in the articles on PNTs. When evaluating the effect of radiotherapy on tumor-related pain, data on analgesic use is of particular value. Radiotherapy effectively relieves pain in weeks to months; during the period, analgesic usage may be increased in certain cases. This increase in analgesic use may confound the analgesic effect of radiotherapy, and lead to overestimation of the response to irradiation [15], [16]. The present study demonstrated that 30% of the PBM articles and approximately half of the PNT articles did not report on analgesic usage. Information on analgesic usage should be recorded and evaluated in future studies, if the additional requirement of study resources is acceptable. The International Consensus Endpoint considers both pain intensity and analgesic use, thus enabling adequate estimation of the pain response [9], [10]. According to the International Consensus Endpoint, responders to radiotherapy have been demonstrated to experience an improvement in both quality of life and pain interference for PBMs [16], [17], [18], [19], [20], [21], [22]; improvements have also been noted for painful tumors in general, including both PBMs and PNTs [11]. Further studies are warranted for investigating the association between the pain response with quality of life and pain interference after radiotherapy for PNTs; available data in this regard are limited. After radiotherapy for painful tumors, the presence of non-index pain, that is more intense than the index pain, negatively influences the interference with daily activities [12]. Information regarding non-index pain was not reported in any of the articles included in the present study, and is worth recording and reporting in the future. The scope of our study is limited by the inclusion of articles published in only 2 radiation oncology journals for analysis. In a cumulative meta-analysis, only one third (9/27) of the included randomized trials on single vs multiple fractions for metastatic bone pain were published in these 2 journals [23], suggesting the presence of significant potential bias in our study. Since our findings are based on articles published in high-impact radiation oncology journals, they may be biased in favor of pain assessment of high quality. There may still be further scope for improvement in pain evaluation in studies published in these journals. In general, pain assessment in radiation oncology may be equivalent or worse. Another limitation of our study is that only one author screened and evaluated the articles. We demonstrated insufficient consistencies in the assessment of pain response in articles on both PBMs and PNTs. In evaluating the palliative effect of radiotherapy, consistent assessment of endpoints is crucial with both conventional radiotherapy and advanced technical therapy, including stereotactic body radiotherapy. In future studies on painful tumors, the International Consensus Endpoint should be utilized for both PBMs and PNTs to ensure consistency. In addition, data on non-index pain should be reported to enable comprehensive evaluation of patients’ pain.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  22 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC.20 randomized trial.

Authors:  Edward Chow; Ralph M Meyer; Bingshu E Chen; Yvette M van der Linden; Daniel Roos; William F Hartsell; Peter Hoskin; Jackson S Y Wu; Abdenour Nabid; Caroline J A Tissing-Tan; Bing Oei; Scott Babington; William F Demas; Carolyn F Wilson; Rebecca K S Wong; Michael Brundage
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 3.  Radiotherapy for pain.

Authors:  S Culleton; S Kwok; E Chow
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-12-18       Impact factor: 4.126

4.  Comparison of pain response and functional interference outcomes between spinal and non-spinal bone metastases treated with palliative radiotherapy.

Authors:  Liang Zeng; Edward Chow; Liying Zhang; Shaelyn Culleton; Lori Holden; Florencia Jon; Luluel Khan; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal
Journal:  Support Care Cancer       Date:  2011-04-08       Impact factor: 3.603

5.  International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases.

Authors:  Edward Chow; Jackson S Y Wu; Peter Hoskin; Lawrence R Coia; Soren M Bentzen; Peter H Blitzer
Journal:  Radiother Oncol       Date:  2002-09       Impact factor: 6.280

6.  Survey on use of palliative radiotherapy in hospice care.

Authors:  Stephen Lutz; Carol Spence; Edward Chow; Nora Janjan; Stephen Connor
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

7.  Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases?

Authors:  K Harris; K Li; C Flynn; E Chow
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-06-12       Impact factor: 4.126

Review 8.  Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis.

Authors:  Marieke H J van den Beuken-van Everdingen; Laura M J Hochstenbach; Elbert A J Joosten; Vivianne C G Tjan-Heijnen; Daisy J A Janssen
Journal:  J Pain Symptom Manage       Date:  2016-04-23       Impact factor: 3.612

9.  Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines.

Authors:  M Fallon; R Giusti; F Aielli; P Hoskin; R Rolke; M Sharma; C I Ripamonti
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 51.769

10.  Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.

Authors:  Milda Rudzianskiene; Arturas Inciura; Rolandas Gerbutavicius; Viktoras Rudzianskas; Andrius Macas; Renata Simoliuniene; Ruta Dambrauskiene; Greta Emilia Kiavialaitis; Elona Juozaityte
Journal:  Strahlenther Onkol       Date:  2017-06-01       Impact factor: 3.621

View more
  1 in total

1.  Palliative radiotherapy for painful lymph node metastases.

Authors:  Kohsei Yamaguchi; Tetsuo Saito; Ryo Toya; Etsushi Tomitaka; Tomohiko Matsuyama; Yoshiyuki Fukugawa; Takahiro Watakabe; Hirohito Otsuka; Natsuo Oya
Journal:  Radiat Oncol       Date:  2021-09-16       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.